Education, Science, Technology, Innovation and Life
Open Access
Sign In
  1. Home
  2. Journals
  3. MEDS Clinical Medicine
  4. Vol 4, Issue 7, 2023

Study on the Mechanism of Yiguan Jian in the Treatment of Liver Fibrosis Based on Network Pharmacology

Download as PDF

DOI: 10.23977/medsc.2023.040719 | Downloads: 3 | Views: 265

Author(s)

Zhang Chunxia 1, Yang Xingwu 2

Affiliation(s)

1 Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, 712046, China
2 Affiliated Hospital of Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, 712000, China

Corresponding Author

Yang Xingwu

ABSTRACT

Through the method of network pharmacology, we discussed the possible pharmacological mechanism of consisten decoction in treating liver fibrosis. We used TCMSP and HERB database and related literature to screen the ingredients of traditional Chinese medicine. The key Target of active ingredients was obtained by Swiss Target Prediction analysis platform, and the disease target information was obtained by GeneCards, OMIM and Drugbank database. The intersection targets of drugs and diseases were obtained using the Draw Venn Diagram platform, and the PPI analysis was performed on the intersection targets in the String database. The intersection targets were uploaded to the DAVID6.8 database for GO function and KEGG path enrichment analysis. The "component-target-signal path" network diagram was constructed using Cytoscape3.9.1 software. Resultly, 25 active ingredients were screened, including quercetin, stigmasterol, β-sitosterol and other core ingredients. There were 621 potential targets for the treatment of liver fibrosis with Yiguan decoction, and 18 key targets were obtained by protein interaction network analysis of intersection targets. GO and KEGG enrichment analysis showed that the key targets exert the functions of protein binding, ATP binding and protein kinase activity through biological processes such as signal transduction, apoptosis, cell proliferation and RNA transcription regulation. It regulated liver fibrosis by participating in hepatitis B signaling pathway, cancer pathway, pancreatic cancer signaling pathway, tumor PD-1 checkpoint pathway, etc. In conclusion, the core components of lucobo saponin, saponin and 2' -hydroxymethylololic acid may be involved in signaling pathways such as PD-L1 expression and PD-1 checkpoint in hepatitis B pathway, cancer pathway, pancreatic cancer and tumor, and act on gene targets such as STAT3, SRC and HSP90AA1 to play an anti-fibrosis role.

KEYWORDS

Consistent frying; Liver fibrosis; Network pharmacology

CITE THIS PAPER

Zhang Chunxia, Yang Xingwu, Study on the Mechanism of Yiguan Jian in the Treatment of Liver Fibrosis Based on Network Pharmacology. MEDS Clinical Medicine (2023) Vol. 4: 118-127. DOI: http://dx.doi.org/10.23977/medsc.2023.040719.

REFERENCES

[1] Scott L. Friedman. Mechanisms of Hepatic Fibrogenesis [J]. Gastroenterology, 2008, 134(6):1655-1669. 
[2] Ke Mengqiong, Gao Xingliang, Gao Bo, et al. Research progress of traditional Chinese medicine in the treatment of liver fibrosis [J]. Journal of Hubei University for nationalities (Medical Edition), 2016, 33(4):59-61. 
[3] Zhu Xiaodong, Di Xueshi, Yang Jialu, et al. Mechanism of Yinchenhao Decoction in Treating Hepatic Fibrosis Based on Network Pharmacology [J]. Acta Chinese Medicine and Pharmacology, 2021, 49(6):29-36. 
[4] Gou Yanpeng, Liu Weiwen. Analysis on compatibility of Yiguanjian [J]. China's Naturopathy, 2022, 30(21):23-25. 
[5] Yang Mengdie, Cai Feifei, Wu Rong, et al. Network Pharmacological Analysis of Yi-Guan Decoction on “Different Diseases with Same Treatment” [J]. World Science and Technology-Modernization of traditional Chinese Medicine, 2017, 19(12):1912-1919. 
[6] Xia Jing, Ba Yuanming, Li Tian'e. Shao Chaodi's clinical experience in clinical application [J]. Liaoning Journal of Traditional Chinese Medicine, 2014, 41(9):1828-1829. 
[7] Gu Qing. Clinical application of Yiguan decoction [J]. Nei Mongol Journal of Traditional Chinese Medicine, 2012, 31(23):126-128. 
[8] Di Xueshi, Chen Zhao, Jia Yusong, et al. Investigation of the mechanism of the effect of Qinge pill on postmenopausal osteoporosis based on network pharmacology [J]. Chinese Journal of Osteoporosis, 2021, 27(3):364-371. 
[9] Pei Guochao, Chen Zhiqiang, Ma Yun, et al. Network Pharmacological study on the Mechanism of Astragalus-Shengdi in the treatment of Diabetic Nephropathy [J]. Chinese Journal of Integrated Traditional and Western Nephrology, 2022, 23 (9): 786-788+849. 
[10] Li Manbiao, Li Jinyu, Feng Duiping. Research advances in the reversal of liver fibrosis [J]. Journal of Clinical Hepatology, 2023, 39(1):193-198. 
[11] Chen Peng, Nie Yuan, Zhu Xuan. Research progress of endoplasmic reticulum stress signaling pathway in liver fibrosis [J]. Chinese Bulletin of Life Sciences, 2022, 34(11):1402-1408. 
[12] Jacopo Baglieri, et al. The Role of Fibrosis and Liver-Associated Fibroblasts in the Pathogenesis of Hepatocellular Carcinoma [J]. International Journal of Molecular Sciences, 2019, 20(7):1723-1723. 
[13] Li Qingqing, et al. Research Progress on Pathogenesis of Liver Fibrosis and Anti-liver Fibrosis of Traditional Chinese Medicine [J]. Journal of Jianghan University:Natural Science Edition, 2023, 51(3):75-81. 
[14] Yu Gong, Li Lu, Hu Qiao, et al. Effect of Compatibility of Fructus Meliae Toosendan in Yiguan Decoction on Tumor Proliferation in H22 Mice [J]. Journal of Jiangxi University of Traditional Chinese Medicine, 2020, 32(4):91-94. 
[15] Shi Cuifen, Xie Bin, Zhang Hanshun, et al. Effects of Fructus Meliae Toosendan Compatibility in Yi Guan Decoction Apoptosis of H22 Tumor Bearing Mice [J]. Modernization of Traditional Chinese Medicine and Materia Medica-World Science and Technology, 2022, 24(7):2710-2716. 
[16] Campana Lara, Iredale John P. Regression of Liver Fibrosis [J]. Seminars in liver disease, 2017, 37(1):1-10. 
[17] Natarajan Vaishaali, Harris Edward N, Kidambi Srivatsan, et al. SECs (Sinusoidal Endothelial Cells), Liver Microenvironment, and Fibrosis [J]. BioMed research international, 2017, 2017:4097205. 
[18] Liu Wenlan, You Hongjie, Zhao Qingzhou, et al. Features of hepatic fibrosis in rats with Yin deficiency syndrome and the intervention effects of Yiguanjian [J]. China Medical Herald, 2015, 12(7):7-10+18. 
[19] Bai Chen, Che Niancong, Liu Wenlan, et al. Study on antagonistic effect of Yiguanjian Decoction on hepatic fibrosis in rats [J]. China Journal of Traditional Chinese Medicine and Pharmacy, 2015, 30(3):815-817. 
[20] Natascha Roehlen, Emilie Crouchet, Thomas F. Baumert, et al. Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives [J]. Cells, 2020, 9(4):875-875. 
[21] Detlef Schuppan, Muhammad Ashfaq-Khan, Ai Ting Yang, et al. Liver fibrosis: Direct antifibrotic agents and targeted therapies [J]. Matrix Biology, 2018, 6869:435-451. 
[22] Zhu Yue, Gao Lu, Lian Lihua, et al. Betulinic acid mediates STAT3 signaling pathway in regulating hepatic fibrosis [J]. Chinese Pharmacological Bulletin, 2021, 37(6):832-838. 
[23] Feng Yinyi, Yan Jiongyi, Xia Xing, et al. Effect and mechanism of total flavonoids of Lichi Semen on CCl4-induced liver fibrosis in rats,and prediction of Q-marker [J]. China Journal of Chinese Materia Medica, 2020, 45(23):5722-5731. 
[24] Ou Shiyu, Du Ling, Wei Jie, et al. Effects of total flavone from Litchi chinensis sonn on rats with hepatic fibrosis through JAK2/STAT3 signaling pathway [J]. Laboratory Medicine and Clinic, 2022, 19(23):3216-3219.

Subscription
E-Mail Alert
Most popular papers
Call for Special Issue
Publication Ethics & OA Statement
Plagiarism Policy
Contact Us
Downloads: 4565
Visits: 197703

Sponsors, Associates, and Links

All published work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright © 2016 - 2031 Clausius Scientific Press Inc. All Rights Reserved.